Feed HEPA
HE

Hepion Pharmaceuticals, Inc.

HEPA · OTC

$0.08 +7.18% (+$0.01)
1M +26.07%
Market Cap $835.4K
P/E Ratio -
Div. Yield -
ROE 139.73%
Piotroski F-Score Weak
1/9
Valuation
100 /100
Cheap
P/B 0.65x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining
Book val. growth 62.32%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 219.39%
ROE 139.73%
ROA 165.42%
Debt
69 /100
Low
Debt/Equity 0.00x
Current ratio 3.91x
Int. coverage -124.87x
Stability
19 /100
Unstable
Beta 1.76x
EPS volatility 55.17%
Profitable years 0

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre HEPA
Online

Despre companie

Hepion Pharmaceuticals, Inc. (HEPA) is a biotechnology company focused on the research and development of therapies for liver diseases and metabolic disorders. Headquartered in the United States, the company aims to utilize its drug candidates to treat diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepion Pharmaceuticals seeks to develop innovative pharmaceutical solutions for patients with these serious health conditions. Shares of Hepion Pharmaceuticals, Inc. (HEPA), listed on the NASDAQ, can be an appealing choice for investors seeking investment opportunities in the biotechnology and liver disease treatment sector.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Gary S. Stetz

Employees

2

Headquarters

Morristown

Evenimente viitoare

14 OCT.

Earnings

Upcoming earnings report

25d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.